News
NewsPharma Pulse
Academy
Publications
Partner Perspectives
More
Webcasts
Resources
Conferences
Conference CoverageConference Listing
Events
Videos
VideosPeer Exchange
Podcasts
Editorial PodcastsSponsored Podcasts

Subscribe

  • News
  • Academy
  • Publications
  • Partner Perspectives
  • Webcasts
  • Resources
  • Conferences
  • Events
  • Videos
  • Podcasts
  • Subscribe
  • Brand & Product Security
    • Legal & Regulatory
    • Trade & Brand Protection
    • Traceability
  • Business and Finance
  • Cold Chain
    • Containers & Shippers
    • Software
    • Devices
  • Commercial Channels
  • Data & Technology
    • Real World Data
    • Digitalization
    • Artificial Intelligence
  • Logistics & Transportation
    • Manufacturing & Packaging
    • 3PL
    • Supply Chain
  • Market Access
    • Pricing
    • Commercialization
    • Trade & Channel
  • Opinion
  • Patient Support
    • Patient Assistance Programs
    • HUB Services
    • Adherence
Spotlight -
Digital Editions|
Security|
Asembia AXS25 Summit
Advertisement

Harry S. Bloch

Advertisement

Articles by Harry S. Bloch

Provisional patent technology filed for cardiovascular disease is for sale or joint venture

ByHarry S. Bloch
April 10th 2019

Combining sublingual nitroglycerin and aspirin in a tablet or other embodiments could be a significant global market opportunity

Advertisement

Latest Updated Articles

  • Provisional patent technology filed for cardiovascular disease is for sale or joint venture
    Provisional patent technology filed for cardiovascular disease is for sale or joint venture

    Published: April 10th 2019 | Updated:



Advertisement
Advertisement

Trending on Pharmaceutical Commerce

1

Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues

2

Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint

3

Why Regulatory Sandboxes Offer a Safe Space for AI Innovation in Healthcare

4

LogiPharma USA 2025: What Topics Do You Think Will headline the 25th LogiPharma USA?

5

Lupin Invests $250 Million in New Coral Springs Manufacturing Facility to Bolster US Respiratory Drug Supply

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us